As such we focused on using Braf/Nf1 allografts to determine whether we could identify a more effective therapy for these genetically distinct tumors....In contrast, these tumors were more sensitive to the MEK inhibitor PD0325901 (Fig. 4C, blue), which effectively suppressed phospho-ERK in vivo.